Cell Source, Inc. is a cell therapy company focused on immunotherapy that develops proprietary immune system management technology known as Veto Cell technology to induce transplant tolerance and enable safer hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapies. The technology originates from research licensed from Yeda Research & Development Company Limited and has been advanced in collaboration with MD Anderson. By promoting sustained chimerism, the company aims to reduce graft-versus-host disease, prevent viral infections, and enhance the graft-versus-leukemia effect in blood cancer patients. Beyond hematologic malignancies, the platform is being explored for broader oncology applications such as solid tumors treated with allogeneic CAR-T cells, for organ transplantation to lessen reliance on lifelong immunosuppression, and for non‑malignant hematologic disorders like sickle cell disease and type 1 diabetes where stem cell transplant could be curative if made safer. Veto cells are a specialized population of immune cells that can inhibit the activity of natural killer and T lymphocytes, thereby creating a state of specific tolerance toward donor antigens while preserving overall immune competence.
The company has not generated any revenue to date and funds its operations through equity and debt financings. From October 2023 through the filing date, it sold 210,132 units in a private placement of Series B Convertible Preferred Stock at $7.50 per unit, raising $1,576,000 in gross proceeds and issuing warrants to purchase 2,364,000 shares of common stock. Additionally, the company has issued notes payable, with past‑due balances of $5,663,000 as of September 30, 2024, and relies on these financing sources to cover research and development, clinical trial costs, and general and administrative expenses. Interest expense on the outstanding notes increased to $730,539 for the nine months ended September 30, 2024, reflecting the growing debt burden as the company continues to fund its operations.
Cell Source operates within the highly competitive cell therapy and immunotherapy industry, where success depends on overcoming immune-related barriers to transplantation and engineered cell therapies. Its Veto Cell platform seeks to differentiate itself by enabling transplant tolerance with only minimal immunosuppression, addressing a limitation of current hematopoietic stem cell transplant and CAR‑T approaches. The company’s developmental stage is pre‑revenue, with ongoing preclinical studies and a Phase 1/2 clinical trial at MD Anderson that has treated fifteen patients with haploidentical hematopoietic stem cell transplantation under reduced intensity conditioning using Veto Cells, showing no toxicity and successful engraftment to date. While numerous competitors focus on refining immunosuppressive regimens or developing autologous cell therapies to avoid graft‑versus‑host disease, Cell Source’s approach aims to achieve tolerance without compromising the patient’s ability to fight infections or resist tumor recurrence.
The company’s intended customers are patients requiring hematopoietic stem cell transplantation, organ transplantation, or chimeric antigen receptor T‑cell therapy, as well as the hospitals and treatment centers that administer these procedures. Early clinical experience has been gathered through the MD Anderson trial, which enrolled fifteen patients receiving haploidentical transplants, indicating a initial focus on individuals with high‑risk blood cancers lacking matched donors. Broader future markets include recipients of solid‑organ transplants and those with inherited blood disorders who could benefit from safer stem‑cell based therapies. The company also engages with academic medical centers and research institutions to advance its preclinical programs, positioning itself to serve a network of transplant centers that may adopt the Veto Cell platform upon regulatory approval.